ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 5, 2017

9:00AM-11:00AM
Abstract Number: 667
Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 663
Urinary Tumor-Necrosis Factor-like Weak Inducer of Apoptosis Is an Important Biomarker for Renal Lupus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 128
Use of Machine Learning and Traditional Statistical Methods to Classify RA-Related Disability Using Administrative Claims Data
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 260
Use of Positron Emission Tomography for the Diagnosis of Aortitis. a Study of 170 Patients from a Single Center
Imaging of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 460
Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission.  Pre-Eliminary Results of a Study of 5 Years of Follow-up
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
9:00AM-11:00AM
Abstract Number: 304
Usefulness of Consecutive Doppler Ultrasound Examinations for Detecting Deep Venous Thrombosis during the Perioperative Period in Patients with Osteoporotic Fractures of the Proximal Femur
Orthopedics, Low Back Pain and Rehabilitation Poster
9:00AM-11:00AM
Abstract Number: 117
Using Goutpro to Make Medical Trainees Gout Pros- a Single Blinded Randomized Control Study
ARHP Education Poster
9:00AM-11:00AM
Abstract Number: 104
Utility of a Virtual Rheumatology Clinic for Community Based Internal Medicine Residency Program
Education Poster
9:00AM-11:00AM
Abstract Number: 370
Validation of 2016 ACR/EULAR Classification Criteria of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis in Japanese Patients
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous
9:00AM-11:00AM
Abstract Number: 248
Validation of Objective Quantification System for Disease Progression in Patients with Juvenile Idiopathic Arthritis
Imaging of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 586
Validation of Online Calibration Modules for the Spondyloarthritis Research Consortium of Canada MRI Scores Based on Real-Time Experiential Learning
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I
9:00AM-11:00AM
Abstract Number: 94
Validity Evidence for an Objective Structured Clinical Examination Station to Assess Knee Arthrocentesis Skill
Education Poster
9:00AM-11:00AM
Abstract Number: 464
Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
9:00AM-11:00AM
Abstract Number: 701
Variability in ICAP (International Consensus on ANA Patterns) Pattern Reporting in Testing for Antinuclear Antibodies (ANA) By Indirect Immunofluorescence Assay (IFA)
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 700
Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
  • «Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology